Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 1
2006 5
2007 4
2008 3
2009 5
2010 6
2011 5
2012 3
2013 1
2014 3
2015 2
2016 3
2017 3
2018 5
2019 7
2020 8
2021 7
2022 4
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated greater and faster skin clearance than etanercept and ustekinumab, with consistent long-term efficacy, safety and durability of response. Clinical trial data and …
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated greater and faster skin clea …
Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tian CC, Ai XC, Ma JC, Hu FQ, Liu XT, Luo YJ, Tan GZ, Zhang JM, Li XQ, Guo Q, Zeng FQ, Shi ZR, Wang L. Tian CC, et al. Ann Allergy Asthma Immunol. 2022 Sep;129(3):360-365.e1. doi: 10.1016/j.anai.2022.05.009. Epub 2022 May 19. Ann Allergy Asthma Immunol. 2022. PMID: 35598882
OBJECTIVE: To compare the efficacy and safety of IVIG and systemic steroids in conjunction with or without etanercept, a tumor necrosis factor-alpha inhibitor, for patients with SJS/TEN. METHODS: We undertook a retrospective review of 41 patients with SJS/TEN admitted to o …
OBJECTIVE: To compare the efficacy and safety of IVIG and systemic steroids in conjunction with or without etanercept, a tumor necros …
Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review.
Husein-ElAhmed H, Steinhoff M. Husein-ElAhmed H, et al. J Dermatolog Treat. 2022 Nov;33(7):2886-2893. doi: 10.1080/09546634.2022.2089331. Epub 2022 Jun 20. J Dermatolog Treat. 2022. PMID: 35694729 Free article. Review.
These cases implicated two cases induced by adalimumab, three by efalizumab, three by etanercept, six by ustekinumab, and one case by secukinumab. Mean period of latency until the BIBP developed was time 5.12 3.44 weeks for TNF-alpha blockers, and 28.66 26.27 weeks for ust …
These cases implicated two cases induced by adalimumab, three by efalizumab, three by etanercept, six by ustekinumab, and one case by …
Regulating Fibrocartilage Stem Cells via TNF-α/Nf-κB in TMJ Osteoarthritis.
Bi R, Chen K, Wang Y, Luo X, Li Q, Li P, Yin Q, Fan Y, Zhu S. Bi R, et al. J Dent Res. 2022 Mar;101(3):312-322. doi: 10.1177/00220345211037248. Epub 2021 Sep 13. J Dent Res. 2022. PMID: 34515572
Surgically induced TMJOA Sprague-Dawley rats were generated with BAY 11-7082 (5 mg/kg, every 3 d) or vehicle subcutaneous injection to investigate the functional role of TNF-alpha/Nf-kappaB in TMJOA. Anterior disc displacement (ADD) rabbits were used to analyze the therape …
Surgically induced TMJOA Sprague-Dawley rats were generated with BAY 11-7082 (5 mg/kg, every 3 d) or vehicle subcutaneous injection to inves …
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events.
Murdaca G, Colombo BM, Puppo F. Murdaca G, et al. Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):557-65. doi: 10.1177/039463200902200301. Int J Immunopathol Pharmacol. 2009. PMID: 19822072 Free article. Review.
The ongoing progresses in the knowledge of the pathogenic mechanisms of various inflammatory or immune-mediated diseases and the availability of innovative biotechnological approaches have lead to the development of new drugs which add to conventional treatments. TNF-alpha …
The ongoing progresses in the knowledge of the pathogenic mechanisms of various inflammatory or immune-mediated diseases and the availabilit …
TNF-α blockers for the treatment of Kawasaki disease in children.
Yamaji N, da Silva Lopes K, Shoda T, Ishitsuka K, Kobayashi T, Ota E, Mori R. Yamaji N, et al. Cochrane Database Syst Rev. 2019 Aug 16;8(8):CD012448. doi: 10.1002/14651858.CD012448.pub2. Cochrane Database Syst Rev. 2019. PMID: 31425625 Free PMC article.
OBJECTIVES: To evaluate the efficacy and safety of using TNF-alpha blockers (i.e. infliximab and etanercept) to treat children with Kawasaki disease. SEARCH METHODS: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, …
OBJECTIVES: To evaluate the efficacy and safety of using TNF-alpha blockers (i.e. infliximab and etanercept) to treat children with K …
The Role of Etanercept in Controlling Clinical and Radiological Progression in Rheumatoid Arthritis: A Systematic Review.
Ejaz S, Gurugubelli S, Prathi SK, Palou Martinez Y, Arrey Agbor DB, Panday P, Yu AK. Ejaz S, et al. Cureus. 2024 Apr 12;16(4):e58112. doi: 10.7759/cureus.58112. eCollection 2024 Apr. Cureus. 2024. PMID: 38738082 Free PMC article. Review.
Etanercept (ETN) is a disease-modifying anti-rheumatic drug (DMARD) used in the treatment of rheumatoid arthritis (RA) that works as a tumor necrosis factor inhibitor (TNF inhibitor) by blocking the effects of naturally occurring TNF. ...Predefined eligibility criteria wer …
Etanercept (ETN) is a disease-modifying anti-rheumatic drug (DMARD) used in the treatment of rheumatoid arthritis (RA) that works as …
Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
Mease P. Mease P. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S116-21. Clin Exp Rheumatol. 2002. PMID: 12463460 Review.
Etanercept was generally well tolerated throughout this trial. A phase 3 trial confirmed the efficacy and safety of etanercept in PsA, with 59% of etanercept-treated patients meeting the ACR20 improvement criteria at 12 weeks compared with 15% of placebo-trea …
Etanercept was generally well tolerated throughout this trial. A phase 3 trial confirmed the efficacy and safety of etanercept …
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Mikkelsen RR, Hundahl MP, Torp CK, Rodríguez-Carrio J, Kjolby M, Bruun JM, Kragstrup TW. Mikkelsen RR, et al. Eur J Pharmacol. 2022 Jun 15;925:174998. doi: 10.1016/j.ejphar.2022.174998. Epub 2022 May 6. Eur J Pharmacol. 2022. PMID: 35533739 Free article. Review.
A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazine were found. RESULTS: Canakinumab and colchicine significantly reduced the risk of CVD, whereas methotrexate did not. ...Anakinra and hydr …
A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazi …
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.
Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Behrens F, et al. Rheumatology (Oxford). 2015 May;54(5):915-26. doi: 10.1093/rheumatology/keu415. Epub 2014 Oct 27. Rheumatology (Oxford). 2015. PMID: 25349441 Review.
CONCLUSION: Available evidence on the efficacy and safety of TNF inhibitor monotherapy vs add-on MTX therapy shows little or no improvement with combination therapy, although the use of concomitant MTX appears to prolong TNF inhibitor drug survival of mAb TNF inhibitors. . …
CONCLUSION: Available evidence on the efficacy and safety of TNF inhibitor monotherapy vs add-on MTX therapy shows little or no impro …
68 results